Date | Title | Description | |
---|---|---|---|
10 May 2023 | On P&L | The Company releases the first quarter 2023 financial results presentation | Download |
10 May 2023 | On P&L | The Company releases the press release related to the first quarter 2023 financial results | Download |
25 Apr 2023 | On business and financial situation | ROVI commences clinical development of a new three-monthly formulation of Letrozole (Letrozole LEBE) | Download |
21 Feb 2023 | On business and financial situation | The Company releases the full year 2022 financial results presentation. | Download |
21 Feb 2023 | On business and financial situation | The Company releases the press release related to the full year 2022 financial results. | Download |
Pages
Date | Title | Description | |
---|---|---|---|
15 Dec 2022 | On Corporate Governance | The Company informs about changes in the Board of Directors and the creation of an Advisory Committee. | Download |
04 Oct 2022 | On business and financial situation | The Company informs that it has signed a joint venture agreement with Càrniques Ceirà and Grupo Costa to construct a plant for the production of compounds of high technological value. | Download |
03 Oct 2022 | Liquidity and counterparty agreements | Liquidity contract: transactions conducted in the third quarter of 2022 | Download |
29 Jul 2022 | Other relevant información | On 26 July 2022 the public deed relating to the Company’s share capital decrease was registered with the Commercial Registry of Madrid. | Download |
27 Jul 2022 | On business and financial situation | The Company releases the first half 2022 financial results presentation | Download |
Pages
Date | Title | Description | |
---|---|---|---|
06 Apr 2017 | Contratos de liquidez y contrapartida | Liquidity contract: transactions conducted in the first quarter of 2017 | Download |
13 Mar 2017 | Otros sobre negocio y situación financiera | The Company releases the presentation related to its biosimilar of Enoxaparin | Download |
07 Mar 2017 | Otros sobre negocio y situación financiera | ROVI informs that the Decentralised procedure used for the registration of its biosimilar of enoxaparin has been completed with positive outcome | Download |
16 Feb 2017 | Otros sobre Gobierno Corporativo | The Company informs about the agreements adopted by the Board of Directors | Download |
16 Feb 2017 | Informe anual de remuneraciones de los consejeros | ROVI releases the 2016 annual report regarding remuneration of the members of the Board of Directors | Download |